CHCheng-Long Huang

Cheng-Long Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cheng-Long Huang has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Motility

    by Cheng-Long Huang

  • Motility

    by Cheng-Long Huang

  • Open Access

    Adenoviral vector expressing short hairpin RNA targeting Wnt2B has an effective antitumour activity against Wnt2B2-overexpressing tumours

    by Dage Liu, Kyuichi Kadota, Masaki Ueno, Nariyasu Nakashima, Hiroyasu Yokomise, Cheng-Long Huang


    • 1 March 2011
      • Vol. 64  (3) , 187-90

    [Prognosis of surgically treated large cell neuroendocrine carcinoma].

    by Natsumi Matsuura, Nariyasu Nakashima, Hitoshi Igai, Shintarou Tarumi, Sung-Soo Chang, Noriyuki Misaki, Dage Liu, Tetsuhiko Go, Shinya Ishikawa, Cheng-Long Huang, et al.

    Large cell neuroendocrine carcinoma (LCNEC) is a relatively rare tumor in malignant lung neoplasms. The prognosis of LCNEC is poor and there is no consensus on the treatment for LCNEC. We report our retrospective assessment of 11 patients of LCNEC from 1999 to 2008. Three of 11 patients had malignant exudate at thoracotomy. Seven patients received limited resection. There was a recurrence even after complete surgical resection in its early stage. Four patients received platinum-based chemotherapy for adjuvant therapy or recurrence. The response to platinum-based chemotherapy was relatively good and may be comparable to that of small cell lung cancer. The overall 5-year survival rate was 30.3%. Pulmonary LCNEC represents an aggressive tumor and multimodal treatment is required.


  • Motility

    by Cheng-Long Huang

  • Open Access

    Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer

    by Cheng-Long Huang, Nariyasu Nakashima, Dage Liu, Masaki Ueno, Hiroyasu Yokomise

    Survivin, a member of the inhibitor of apoptosis protein family, affects tumorigenesis. Recently, survivin is reported to be a target of the canonical Wnt pathway, which activates the transcription of various tumor-associated target genes. One hundred and twenty-two non-small cell lung cancers (NSCLCs) were investigated to evaluate survivin gene expression in relation to the expression of Wnt1 (a novel member of the canonical Wnt pathway) and Wnt5a (a novel member of the non-canonical Wnt pathway). The survivin gene expression was evaluated by semi-quantitative RT-PCR. The protein expression of pan-survivin, Wnt1, and Wn5a were investigated by immunohistochemistry. The apoptotic index and the Ki-67 proliferation index were also evaluated. Sixty-four tumors (52.5%) were survivin-high tumors, 65 tumors were Wnt1-high tumors, and 67 tumors (54.9%) were Wnt5a-high tumors. The standardized survivin gene expression significantly correlated with the apoptotic index (P<0.0001), the Ki-67 proliferation index (P<0.0001), and patient survival (P=0.0467). Furthermore, the percentage of Wnt1-positive tumor cells significantly correlated with the standardized survivin gene expression (P<0.0001). In contrast, the percentage of Wnt5a-positive tumor cells did not correlate with the standardized survivin gene expression. As a result, intratumoral Wnt1 expression significantly correlated with the apoptotic index (P<0.0001), the Ki-67 proliferation index (P<0.0001), and patient survival (P=0.0355). Intra-tumoral Wnt1 overexpression could produce more aggressive NSCLCs by induction of survivin.


    • 1 June 2010
      • Vol. 16  (3) , 194-7

    Progressive growth of primary synovial sarcoma of the lung.

    by Jun Nakano, Hiroyasu Yokomise, Cheng-Long Huang, Noriyuki Misaki, Sung-Soo Chang, Masaya Okuda, Yoshio Kushida, Reiji Haba

    An 80-year-old male was admitted because of a giant mass in the left lower lobe of the lung on a routine chest X-ray. Chest computed tomography verified this to be a well-defined heterogeneous mass as described with no associated lymphadenopathy. FDG-PET depicted moderately marginal FDG uptake. The patient underwent a left lower lobectomy and lymphadenectomy. Grossly, the tumor measured 60 × 50 mm and was uniformly filled with a pure white, pudding-like friable substance. No lymph node metastasis was observed microscopically. Histologically, the tumor showed a dense proliferation of rounded or spindled malignant cells with a frequent mitotic activity and an increased nuclear-to-cytoplasmic ratio. The immunohistochemical staining was positive for vimentin, negative for cytokeratin, keratin-wide, EMA, CD34. A SYT-SSX2 fusion gene transcript was detected as a result of RT-PCR analysis. Because of these results, the tumor was diagnosed as a monophasic synovial sarcoma.


  • Open Access

    Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane

    by Cheng-Long Huang, Kyuichi Kadota, Dage Liu, Masaki Ueno, Nariyasu Nakasima, Shinya Ishikawa, Masashi Gotoh, Noriyuki Misaki, Sung-Soo Chang, Hiroyasu Yokomise

    Several molecules have been proven to be associated with responsiveness to chemotherapy. A clinical study on the expression of excision repair cross-complementing (ERCC)-1 and class III β-tubulin was conducted in advanced stage non-small cell lung cancer (NSCLC) patients. We investigated 34 resected stage III NSCLC patients treated with induction chemoradiotherapy using carboplatin-taxane. Immunohistochemistry was performed to evaluate the intratumoral expression of ERCC1 and class III β-tubulin. Nineteen tumors (55.9%) were ERCC1-high and 11 (32.4%) were class III β-tubulin-high. There was no correlation between ERCC1 and class III β-tubulin expression (r=0.208). Regarding the pathological effect of induction therapy, the percentage of ERCC1-positive tumor cells was lower in tumors with a major response than in tumors with a minor response (P=0.0851). The percentage of class III β-tubulin-positive tumor cells was significantly lower in tumors with a major response than in tumors with a minor response (P=0.0105). Regarding patient survival, the overall survival was significantly higher in patients with ERCC1-low tumors than in those with ERCC1-high tumors (P=0.0034). The overall survival was also significantly higher in patients with class III β-tubulin-low tumors than in those with class III β-tubulin-high tumors (P=0.0185). Cox regression analysis also demonstrated that ERCC1 (P=0.0467) and class III β-tubulin statuses (P=0.0237) were significant prognostic factors. Co-evaluations of the intratumoral expression of ERCC1 and class III β-tubulin are clinically useful for identifying patient populations responsive to chemotherapy using carboplatin-taxane.


  • Wnt1 overexpression promotes tumour progression in non-small cell lung cancer

    by Cheng-Long Huang, Dage Liu, Shinya Ishikawa, Takashi Nakashima, Nariyasu Nakashima, Hiroyasu Yokomise, Kyuichi Kadota, Masaki Ueno


  • Open Access

    E2F1 Overexpression Correlates with Thymidylate Synthase and Survivin Gene Expressions and Tumor Proliferation in Non–Small-Cell Lung Cancer

    by Cheng-Long Huang, Dage Liu, Jun Nakano, Hiroyasu Yokomise, Masaki Ueno, Kyuichi Kadota, Hiromi Wada

    Purpose: We investigated the clinical significance of E2F1 gene expression in relation to its target genes, thymidylate synthase (TS) and Survivin, in case of non–small-cell lung cancer (NSCLC). Experimental Design: One hundred twenty-seven cases of resected NSCLC were analyzed. Quantitative reverse transcription-PCR was done to evaluate the gene expression of E2F1, TS, and Survivin. Immunohistochemistry was done to investigate the protein expression of E2F1, TS, and Survivin. The Ki-67 proliferation index and the apoptotic index using the terminal deoxyribonucleotidyl transferase–mediated dUTP nick-end labeling method were also evaluated. Results:E2F1 gene expression significantly correlated with the Ki-67 proliferation index (r = 0.487; P < 0.0001), although no correlation was observed between E2F1 gene expression and the apoptotic index. With regard to E2F1 target genes, E2F1 gene expression significantly correlated with TS gene expression (r = 0.709; P < 0.0001) and Survivin gene expression (r = 0.403; P < 0.0001). The overall survival rate was significantly lower in patients with high-E2F1 tumors than in those with low-E2F1 tumors (P = 0.0027), especially among patients with stage II to III NSCLCs (P = 0.0188). A Cox regression analysis showed that the E2F1 status was a significant prognostic factor for NSCLC patients (hazard ratio, 2.052; P = 0.0261). Conclusions: The present study revealed that E2F1 gene expression correlates with TS and Survivin gene expressions and tumor proliferation. During the progression of NSCLC, E2F1 overexpression could produce more aggressive tumors with a high proliferation rate and chemoresistance.